$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
Treatment of Xalkore (crizotinib) in patients with advanced ALK-positive non-small cell lung cancer
2025-10-19 11:44:20
Check Details
Crizotinib (Xalkori) is suitable for ALK-positive non-small cell lung cancer
2025-10-19 11:44:20
Check Details
Entrectinib has long-term clinical efficacy in ROS1-positive non-small cell lung cancer
2025-10-19 11:44:20
Check Details
[Clinical Observation] Xakori (crizotinib) is effective in ROS1-rearranged non-small cell lung cancer
2025-10-19 11:44:20
Check Details
Will the lung cancer targeted drug Gitare be reimbursed by medical insurance? If you want to know, hurry up
2025-10-19 11:44:20
Check Details
What is the out-of-pocket rate for Gyterinib (afatinib)? Everything everyone cares about is here
2025-10-19 11:44:20
Check Details
[New Social Security Regulations] How much can Gefitinib save after medical insurance in 2021?
2025-10-19 11:44:20
Check Details
Will the targeted drug afatinib be reimbursed by medical insurance? List of targeted drugs reimbursed by medical insurance
2025-10-19 11:44:20
Check Details
The greater the side effects of the targeted drug gefitinib, the better the effect? Oncology experts see it this way
2025-10-19 11:44:20
Check Details
How much does a box of Cabozantinib cost? Where can I buy it?
2025-10-19 11:44:20
Check Details
What is the price advantage of Giteri (afatinib) after it is included in medical insurance? Where to buy discounts?
2025-10-19 11:44:20
Check Details
[What you are most concerned about] Will taking the targeted drug gefitinib for three months make the tumor disappear?
2025-10-19 11:44:20
Check Details
1
2
...
3900
3901
3902
3903
3904
3905
3906
...
4152
4153
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Managing Immunotherapy-Related Adverse Events of Tarlatamab-Imdelltra: A Guide to Dual-Specific T Cell Engager Safety
2
Almonertinib Safety Guide: Managing Adverse Reactions in NSCLC Treatment with a 3rd-Gen EGFR TKI
3
Pimitespib Storage Guidelines: Temperature, Humidity & Light Control for Home Use
4
Cemiplimab (Libtayo) Drug Information
5
Mirvetuximab Soravtansine (Elahere): FRα-Targeted ADC for Platinum-Resistant Ovarian Cancer
6
The Cornerstone Therapy for Adrenocortical Carcinoma and Global Guidelines Update
7
Trodelvy® (Sacituzumab Govitecan-hziy): A Life-Changing ADC for Advanced Cancers
8
A Revolutionary Targeted Therapy for Hematological Malignancies
9
A New Option for Advanced Renal Cell Carcinoma Treatment
10
Trametinib (Mekinist): Precision MEK1/2 Inhibition Transforming Cancer Care Short Description:
11
Pirtobrutinib: A Novel BTK Inhibitor Offering Hope for Hematologic Cancer Patients Short Description:
12
Sacituzumab Govitecan: Trop-2 Targeted ADC Clinical Medication Guide